Investment Rating - The investment rating for the company is "Buy" (maintained) [2][18] Core Views - The operating profit has returned to double-digit growth, confirming the performance inflection point for the company [5] - The company achieved a net profit attributable to shareholders of 134.78 billion yuan in 2025, representing a year-on-year growth of 6.5% [5] - The company expects a net profit of 151.39 billion yuan in 2026, with a year-on-year growth rate of 12.3% [5] Financial Performance Summary - **Revenue Forecasts**: - 2024A: 1,028,925 million yuan - 2025E: 1,050,506 million yuan (growth rate of 2.1%) - 2026E: 1,071,653 million yuan (growth rate of 2.0%) [2] - **Net Profit Forecasts**: - 2024A: 126,607 million yuan - 2025E: 134,778 million yuan (growth rate of 6.5%) - 2026E: 151,385 million yuan (growth rate of 12.3%) [2] - **Earnings Per Share (EPS)**: - 2024A: 7.16 yuan - 2025E: 7.68 yuan - 2026E: 8.36 yuan [2] - **Return on Equity (ROE)**: - 2024: 13.8% - 2025: 14.0% - 2026: 14.4% [2] Business Segment Performance - **Life and Health Insurance**: - Operating profit increased by 2.9% to 998 million yuan in 2025 [7] - **Property Insurance**: - Operating profit increased by 13.2% to 169 million yuan in 2025 [7] - **Banking**: - Operating profit decreased by 4.2% to 247 million yuan in 2025 [7] - **Asset Management**: - Operating loss improved to -38 million yuan from -119 million yuan [7] Dividend and Shareholder Returns - The company declared a dividend per share (DPS) of 2.7 yuan for 2025, representing a year-on-year growth of 5.9% [5] - The dividend payout ratio reached 36.4%, maintaining a consistent growth for 14 consecutive years [5] Future Outlook - The company anticipates a gradual recovery in the contract service margin (CSM), which is expected to drive both amortization and operating profit back to growth [5] - The expected net profit for 2026-2028 is projected to be 151.39 billion, 159.95 billion, and 168.06 billion yuan respectively, with growth rates of 12.3%, 5.7%, and 5.1% [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][18] Core Views - The operating profit has returned to double-digit growth, confirming the performance inflection point for the company [5] - The company achieved a net profit attributable to shareholders of 134.78 billion yuan in 2025, representing a year-on-year growth of 6.5% [5] - The company’s new business value (NBV) reached 36.897 billion yuan, a year-on-year increase of 29.3%, driven by growth in both agency and bancassurance channels [5] Financial Performance Summary - **Revenue Forecasts**: - 2024A: 1,028.93 billion yuan - 2025E: 1,050.51 billion yuan (growth rate of 2.1%) - 2026E: 1,071.65 billion yuan (growth rate of 2.0%) [2] - **Net Profit Forecasts**: - 2024A: 126.61 billion yuan - 2025E: 134.78 billion yuan (growth rate of 6.5%) - 2026E: 151.39 billion yuan (growth rate of 12.3%) [2] - **Earnings Per Share (EPS)**: - 2024A: 7.16 yuan - 2025E: 7.68 yuan - 2026E: 8.36 yuan [2] - **Return on Equity (ROE)**: - 2024: 13.8% - 2025: 14.0% - 2026: 14.4% [2] Business Segment Performance - **Life and Health Insurance**: - Operating profit increased by 2.9% to 99.8 billion yuan [7] - **Property Insurance**: - Operating profit increased by 13.2% to 16.9 billion yuan [7] - **Banking**: - Operating profit decreased by 4.2% to 24.7 billion yuan [7] - **Asset Management**: - Operating loss reduced to 3.8 billion yuan from 11.9 billion yuan [7] Dividend and Shareholder Returns - The company declared a dividend per share (DPS) of 2.7 yuan for 2025, a year-on-year increase of 5.9%, maintaining a dividend payout ratio of 36.4% [5] - The static dividend yield for A shares is currently 4.8% [5]

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [4][7] Core Views - The company is experiencing a performance turnaround with continuous operational improvement, highlighted by a low double-digit revenue growth in 2025 and a strong double-digit growth in infant nutrition and care products [1][4] - Adjusted comparable EBITDA is expected to grow by 2% to 6% year-on-year, with an adjusted net profit growth forecast of 15% to 25% [1][4] Summary by Relevant Sections ANC (Adult Nutrition Category) - The company has increased its market share in mainland China, achieving low double-digit growth in 2025, while other expanding markets saw strong double-digit growth [2] - Innovative product categories such as heart health and anti-aging are experiencing robust growth, with Swisse Plus and Little Swisse continuing to expand [2] - The e-commerce market for health products in China is projected to grow by approximately 10% year-on-year, with Swisse outperforming the industry growth rate [2] BNC (Baby Nutrition Category) - The infant nutrition and care segment achieved strong double-digit growth, particularly in infant formula, which significantly outpaced the industry growth rate in mainland China [3] - The company’s strategy of expanding customer acquisition through dedicated infant stores and social media platforms has shown significant results [3] - The infant probiotic and nutritional supplements segment saw low single-digit growth, driven by new product launches and accelerated growth in dedicated stores and online channels [3] PNC (Pet Nutrition Category) - The pet nutrition and care segment achieved high single-digit growth in 2025, with expectations for accelerated growth following product structure optimization and channel adjustments [3] Financial Projections - The company is projected to achieve net profits of 422 million, 584 million, and 714 million RMB for the years 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 886.3%, 38.2%, and 22.3% [4][6] - The expected adjusted net profit for 2025 is between 620 million and 680 million RMB, corresponding to a price-to-earnings ratio (PE) of 12-13x [4]

Equity Market Review and Outlook - The Shanghai Composite Index fell by 1.27%, the CSI 300 dropped by 1.33%, and the ChiNext Index decreased by 3.28% during the week of February 2-6, 2026, amid significant volatility in global resource futures and earnings disclosures from major US tech companies [1][4] - A-shares experienced increased volatility, with a notable drop of 100 points on Monday, followed by a recovery on Tuesday, and a shift to a fluctuating market for the rest of the week, influenced by upstream resource stocks and internet giants [4][5] - The market's risk appetite was constrained, with an average daily trading volume of 24,032 billion, reflecting a decrease from the previous week [4] - The technology sector is becoming increasingly sensitive to negative news, with potential pressure on tech styles as positive factors may be realized following the Two Sessions after the Spring Festival [5] Fixed Income Market Review and Outlook - The bond market saw a flattening yield curve during the week, with the 1-year government bond yield rising by 1.80 basis points to 1.32%, while the 10-year and 30-year yields fell to 1.81% and 2.25%, respectively [2][6] - The bond market is currently experiencing a strong oscillation, with some risk-averse funds flowing into bonds due to increased stock market volatility before the holiday [6][7] - The People's Bank of China has been actively injecting liquidity, with a net injection of 700 billion yuan through MLF in January, and the bond market is expected to remain stable without significant fluctuations in the short term [7] REITs Market Overview - The CSI REITs total return index fell by 0.91% to 1,042.84 points during the week, with most sectors declining, particularly consumption, data centers, and industrial parks [8] - Four new public REITs made progress in the primary market, indicating ongoing developments in the sector [8] Fund Index Performance Tracking - The monetary enhancement strategy index increased by 0.03% for the week, while the short-term bond fund index rose by 0.04% [11] - The mid-to-long-term bond fund index saw a gain of 0.09%, while the low-volatility fixed income plus fund index decreased by 0.04% [11] - The REITs fund index experienced a significant drop of 1.86%, reflecting the overall market trend [11] Investment Strategy Indices - The active stock fund selection index focuses on 15 funds with equal weight, emphasizing performance competitiveness and style stability [12] - The value stock fund selection index includes deep value and quality value styles, assessing companies based on absolute valuation levels and cash flow efficiency [14] - The growth stock fund selection index aims to capture high-growth opportunities, focusing on companies with significant future potential [17] Industry Theme Indices - The pharmaceutical stock fund selection index is constructed based on the intersection of fund holdings and representative indices, ensuring a minimum purity of 60% [19] - The consumer stock fund selection index targets funds with significant holdings in consumer-related sectors, maintaining a minimum purity of 50% [21] - The technology stock fund selection index is based on funds with substantial investments in technology sectors, also ensuring a minimum purity of 60% [24] Other Fixed Income Indices - The convertible bond fund selection index focuses on funds with a high proportion of convertible bonds, assessing performance and risk management [43] - The QDII bond fund selection index includes overseas bonds, prioritizing funds with stable returns and good risk control [44] - The REITs fund selection index emphasizes funds with stable cash flows from quality infrastructure projects [46]

Core Viewpoint - The current fiscal year is becoming a critical turning point for profitability and cash flow for Saputo, as indicated by the Royal Bank of Canada, which has adjusted its assumptions ahead of the company's third-quarter earnings report [1] Group 1: Earnings Forecast - The Royal Bank of Canada maintains its earnings forecast, projecting a third-quarter earnings per share of CAD 0.51, representing a 29% year-over-year increase, although it is below the average expectation of CAD 0.54 [1] - The target price for Saputo's stock has been raised from CAD 42 to CAD 47, while maintaining an "outperform" rating [1] Group 2: Regional Performance Insights - Canadian operations are expected to remain stable and robust, supported by business initiatives and sales growth [1] - Despite ongoing commodity price volatility, the outlook for U.S. operations is described as "constructive" [1] - The business environment in Australia is generally favorable, while in Europe, product mix and efficiency improvements are anticipated to drive moderate margin expansion [1]

Core Insights - Domestic dye prices have been rising recently, with disperse dyes averaging 19 yuan per kilogram on January 29, up 1 yuan from the previous day and 2 yuan from January 21 [1] - Active dye prices also increased to an average of 23 yuan per kilogram on January 29, reflecting a 1 yuan rise from the previous day [1] Price Movements - H-acid market price reached 41.5 yuan per kilogram on January 29, up 1 yuan from January 27 [1] - Zhejiang Longsheng, a major player in the dye industry, raised prices for active and disperse dyes by up to 3000 yuan per ton on January 27 and 28 [1] Market Dynamics - The price increase in dyes is attributed to a combination of cost-push factors and an optimized industry structure [1] - The surge in prices of key upstream raw materials, particularly "reduction agents," has provided strong support for dye prices [1] - Industry leaders are leveraging their integrated supply chain advantages to raise prices, alleviating cost pressures and potentially accelerating the exit of smaller, less competitive producers from the market [1] Industry Outlook - The current developments suggest a potential turning point for the chemical industry, especially in the dye segment, driven by fundamental improvements in supply and demand dynamics [1]

Industry Overview - Domestic dye prices have been continuously rising, with disperse dye prices averaging 19 yuan/kg on January 29, up 1 yuan/kg from the previous day and 2 yuan/kg from January 21. Active dye prices averaged 23 yuan/kg on January 29, also up 1 yuan/kg from the previous day [1] - The price of H acid, a key upstream raw material, reached 41.5 yuan/kg on January 29, increasing by 1 yuan/kg from January 27 [1] - The price increase is attributed to a combination of cost-push factors and an optimized industry structure, with soaring prices of upstream key raw materials providing strong support for dye prices [1] Company Insights - Zhejiang Longsheng has a production capacity of 140,000 tons for disperse dyes and 70,000 tons for active dyes, along with relevant layouts for reducing agents and H acid [2] - It is estimated that for every 10,000 yuan/ton increase in disperse dye prices, there could be a corresponding contribution of 1.24 billion yuan in performance elasticity; for active dyes, a 10,000 yuan/ton increase could contribute 620 million yuan [2] - Qicai Chemical focuses on the R&D, production, and sales of high-performance organic pigments, solvent dyes, and related intermediates, benefiting from the rise in dye prices [2]

Core Viewpoint - The company, HaiMuxing, is expected to report a net loss of 850 million to 910 million yuan for the fiscal year 2025, indicating a further deterioration in performance compared to the previous year due to multiple factors including declining gross margins and increased impairment provisions [2][3] Group 1: Financial Performance - The gross margin has significantly declined from 34.22% in Q3 2022 to 17.76% in Q3 2025, representing a drop of over 48% [3] - The company reported a gross margin of 30.50% for the entire year of 2022, which decreased to 15.20% in the first half of 2025, with a slight recovery to 17.76% in the first three quarters of 2025 [3] - The company has accumulated over 500 million yuan in impairment losses in the first three quarters of 2025, attributed to inventory write-downs and bad debts [5] Group 2: Operational Challenges - The company faces increased operational challenges, reflected in rising inventory turnover days, which reached 526.73 days in 2025 compared to 335.23 days in 2022, and accounts receivable turnover days, which increased to 186 days from 75.61 days in 2022 [5] - The capital liability ratio has risen to 82.36% by Q3 2025, indicating increased debt pressure due to declining operational efficiency and ongoing investments in R&D and overseas expansion [6] Group 3: Market Conditions and Future Outlook - The company has reported a potential turnaround in Q4 2025, with an expected net profit of 2.518 million to 62.52 million yuan, marking a year-on-year increase of 100.76% to 118.92% [7] - The company has over 10 billion yuan in orders on hand, which may support performance in 2026, but confirmation of a sustainable recovery will depend on Q1 2026 data [7] - The company is exploring new technologies in collaboration with industry leaders, but faces challenges in resource allocation across multiple business segments and the need for effective market positioning [8]

Group 1 - The real estate market supply and demand have shown improvement, with sufficient adjustments made, indicating a potential stabilization by 2026, marking a critical year for real estate companies to repair their balance sheets [1] - In a low-interest-rate environment, long-term capital continues to allocate towards commercial real estate, suggesting rapid growth in the commercial management industry [1] - Leading companies in the construction and building materials sector have enhanced their market share and optimized sales channels through five years of adjustments, demonstrating the ability to navigate through cycles, with performance inflection points expected for some companies in 2026 [1] Group 2 - In the public utilities and environmental protection sector, water and electricity companies are preferred for their strong anti-cyclical capabilities and attractive dividend yields [1] - Gas companies are expected to gradually recover their performance as gas prices decline and demand rebounds [1] - Waste-to-energy companies are anticipated to successfully expand overseas, breaking through growth constraints [1]

Core Viewpoint - The company, a leading player in the domestic soybean protein industry, is experiencing a performance turning point due to its full industry chain layout and favorable cost conditions, focusing on non-GMO soybean products [1][2]. Group 1: Company Performance - The company specializes in the full industry chain of non-GMO soybeans, with main products including soybean isolate protein, concentrate protein, textured protein, and non-GMO soybean oil [1]. - In 2025, the company is expected to see a performance turnaround, with Q1-Q3 revenue reaching 1.24 billion yuan, a year-on-year increase of 7.37%, and net profit attributable to shareholders of 147 million yuan, a year-on-year increase of 60% [1]. - The company has actively expanded production to increase sales, and as downstream demand gradually recovers, it anticipates improved financial performance [1]. Group 2: Industry Dynamics - The demand for soybean protein is rapidly growing, driven by health and environmental concerns, with applications in meat processing, plant-based meat, snacks, and health products [1]. - China holds approximately 50% of the global soybean protein market, with the industry size reaching 14.52 billion yuan in 2022, and a CAGR of 3.89% from 2018 to 2022 [1]. - The industry concentration is expected to increase, with the top five companies holding a market share of 60%, and the company itself holding about 10% market share [1]. Group 3: Competitive Advantages - The company has established a high-profit barrier through its full industry chain layout and has a complete product line in soybean protein deep processing, which enhances its competitive advantage [2]. - The company's gross profit margin for soybean protein is significantly higher than the industry average, supported by a focus on high-margin products like soybean concentrate protein and textured protein [2]. - The company has procured a significant amount of low-cost soybean raw materials in early 2025, which, combined with product structure optimization, is expected to enhance its gross profit margin [2]. Group 4: Financial Projections - Revenue projections for the company from 2025 to 2027 are estimated at 1.658 billion yuan, 1.881 billion yuan, and 2.136 billion yuan, representing year-on-year growth of 6.57%, 13.50%, and 13.54% respectively [2]. - Net profit projections for the same period are expected to be 186 million yuan, 215 million yuan, and 266 million yuan, with year-on-year growth of 53.46%, 15.81%, and 23.56% respectively [2].